Sangamo Therapeutics (NASDAQ: SGMO ) stock is rising higher on Tuesday after the clinical-stage genomic medicine company announced a new license agreement. Sangamo Therapeutics has signed a license agreement Genentech for the development of intravenously administered genomic medicines to treat certain neurodegenerative diseases.
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Announces Epigenetic Regulation and Capsid Delivery Agreement with Genentech to Develop Genomic Medicines for Neurodegenerative Diseases.
When small-cap biotech stocks go on a tear, many investors pay attention. Little-known company Sangamo Therapeutics (NASDAQ: SGMO ) is making waves today, with SGMO stock up more than 40% at the time of this writing.
Sangamo Therapeutics, Inc. is almost out of cash, and as such, at risk of bankruptcy. Therefore, investing in this company is not a good idea for most investors. 3 of its assets have updates coming over the next 1–6 months that could realistically bring in a combination of ~$1B of cash & milestones over the next 12–18 months. Due to its history of burning cash and not being able to get a drug ...
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Amy Pooler - Head of Research Nathalie Dubois-Stringfellow - Chief Development Officer Conference Call Participants James Stamos - Jefferies Gena Wang - Barcla...
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2024 FINANCIAL RESULTS.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.